K药-话题@MedSci

#K药#

22篇内容 | 1180人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2089208, encodeId=df7f208920838, content=与安慰剂相比，<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a><a href='/topic/show?id=89a810615bb' target=_blank style='color:#2F92EE;'>#K药#</a>显著延长了完全切除的IB-IIIA期<a href='/topic/show?id=2493130e1a1' target=_blank style='color:#2F92EE;'>#NSCLC#</a>患者的无病生存期，无论<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>表达水平如何，而且无新的安全性问题。派姆单抗可作为完全切除后的IB-IIIA期NSCLC患者的新治疗选择。说明术后辅助也是有效的，那么如果术前做<a href='/topic/show?id=1a5a58e00ad' target=_blank style='color:#2F92EE;'>#新辅助治疗#</a>，术后再做一段时间辅助，会不会更好？？, objectTitle=Lancet Oncol：派姆单抗辅助治疗可显著延长术后IB-IIIA期NSCLC患者的生存期, objectType=article, longId=740057, objectId=aad8e40057a1, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20220919/1663595268646_2110107.JPG, objectUrl=/article/show_article.do?id=aad8e40057a1, replyNumber=0, likeNumber=107, createdTime=2022-09-20, rootId=0, userName=小小医者, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aad8e40057a1, moduleTitle=Lancet Oncol：派姆单抗辅助治疗可显著延长术后IB-IIIA期NSCLC患者的生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aad8e40057a1)], followStatus=false, userIsMember=true, type=1, lengthMark=1), GetTopicListResponse(id=1618739, encodeId=0da11618e3963, content=<a href='/topic/show?id=89a810615bb' target=_blank style='color:#2F92EE;'>#K药#</a>, objectTitle=NEJM重磅：K药一线治疗三阴乳腺癌OS结果终现！, objectType=article, longId=733028, objectId=c77be33028c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c77be33028c3, replyNumber=0, likeNumber=54, createdTime=2022-07-24, rootId=0, userName=12498e0fm84暂无昵称, userId=ae0619946966, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c77be33028c3, moduleTitle=NEJM重磅：K药一线治疗三阴乳腺癌OS结果终现！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c77be33028c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1618738, encodeId=e5121618e3818, content=<a href='/topic/show?id=89a810615bb' target=_blank style='color:#2F92EE;'>#K药#</a>, objectTitle=Lancet：全球半数病例在中国，K药为食管癌患者带来好消息！, objectType=article, longId=216447, objectId=c37e21644ef7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c37e21644ef7, replyNumber=0, likeNumber=40, createdTime=2021-08-31, rootId=0, userName=12498e0fm84暂无昵称, userId=ae0619946966, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c37e21644ef7, moduleTitle=Lancet：全球半数病例在中国，K药为食管癌患者带来好消息！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c37e21644ef7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1618737, encodeId=ee0d1618e3789, content=<a href='/topic/show?id=89a810615bb' target=_blank style='color:#2F92EE;'>#K药#</a>, objectTitle=默沙东联合Surface开展联合疗法研究，或将改善K药耐药性, objectType=article, longId=209545, objectId=c8ee20954549, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c8ee20954549, replyNumber=0, likeNumber=50, createdTime=2021-04-05, rootId=0, userName=12498e0fm84暂无昵称, userId=ae0619946966, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c8ee20954549, moduleTitle=默沙东联合Surface开展联合疗法研究，或将改善K药耐药性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c8ee20954549)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1618736, encodeId=27691618e368c, content=<a href='/topic/show?id=89a810615bb' target=_blank style='color:#2F92EE;'>#K药#</a>, objectTitle=K药在欧盟获批儿科适应症, objectType=article, longId=208754, objectId=64a7208e54b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=64a7208e54b4, replyNumber=0, likeNumber=46, createdTime=2021-03-22, rootId=0, userName=12498e0fm84暂无昵称, userId=ae0619946966, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=64a7208e54b4, moduleTitle=K药在欧盟获批儿科适应症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=64a7208e54b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1618735, encodeId=24f31618e3556, content=<a href='/topic/show?id=89a810615bb' target=_blank style='color:#2F92EE;'>#K药#</a>, objectTitle=K药在欧盟获批儿科适应症, objectType=article, longId=208695, objectId=0ef7208695b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ef7208695b9, replyNumber=0, likeNumber=62, createdTime=2021-03-20, rootId=0, userName=12498e0fm84暂无昵称, userId=ae0619946966, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ef7208695b9, moduleTitle=K药在欧盟获批儿科适应症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0ef7208695b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1618734, encodeId=3b6f1618e345c, content=<a href='/topic/show?id=89a810615bb' target=_blank style='color:#2F92EE;'>#K药#</a>, objectTitle=K药，一年卖了930亿, objectType=article, longId=206851, objectId=3bef2068519a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3bef2068519a, replyNumber=0, likeNumber=41, createdTime=2021-02-07, rootId=0, userName=12498e0fm84暂无昵称, userId=ae0619946966, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3bef2068519a, moduleTitle=K药，一年卖了930亿, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3bef2068519a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1618733, encodeId=67241618e33d2, content=<a href='/topic/show?id=89a810615bb' target=_blank style='color:#2F92EE;'>#K药#</a>, objectTitle=ASCO 2020：K药联合仑伐替尼的“可乐组合”在肾透明细胞癌再显威, objectType=article, longId=195028, objectId=3b871950281b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3b871950281b, replyNumber=0, likeNumber=58, createdTime=2020-06-01, rootId=0, userName=12498e0fm84暂无昵称, userId=ae0619946966, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3b871950281b, moduleTitle=ASCO 2020：K药联合仑伐替尼的“可乐组合”在肾透明细胞癌再显威, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3b871950281b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1618732, encodeId=41821618e3228, content=<a href='/topic/show?id=89a810615bb' target=_blank style='color:#2F92EE;'>#K药#</a>, objectTitle=抢位K药？百济神州PD-1联合化疗一线治疗晚期鳞状非小细胞肺癌III期数据公布, objectType=article, longId=194361, objectId=efad194361a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=efad194361a2, replyNumber=0, likeNumber=43, createdTime=2020-05-20, rootId=0, userName=12498e0fm84暂无昵称, userId=ae0619946966, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=efad194361a2, moduleTitle=抢位K药？百济神州PD-1联合化疗一线治疗晚期鳞状非小细胞肺癌III期数据公布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=efad194361a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1618731, encodeId=68631618e3131, content=<a href='/topic/show?id=89a810615bb' target=_blank style='color:#2F92EE;'>#K药#</a>, objectTitle=AACR 2020：STK11和KEAP1突变影响K药一线治疗PDL1阳性患者（Keynote 042研究）, objectType=article, longId=193109, objectId=bc64193109cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc64193109cc, replyNumber=0, likeNumber=57, createdTime=2020-04-30, rootId=0, userName=12498e0fm84暂无昵称, userId=ae0619946966, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc64193109cc, moduleTitle=AACR 2020：STK11和KEAP1突变影响K药一线治疗PDL1阳性患者（Keynote 042研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc64193109cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1618730, encodeId=a71c1618e30ee, content=<a href='/topic/show?id=89a810615bb' target=_blank style='color:#2F92EE;'>#K药#</a>, objectTitle=患者福音：门槛降低60%，K药援助政策再升级, objectType=article, longId=185566, objectId=e39a18556630, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e39a18556630, replyNumber=0, likeNumber=45, createdTime=2020-01-03, rootId=0, userName=12498e0fm84暂无昵称, userId=ae0619946966, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e39a18556630, moduleTitle=患者福音：门槛降低60%，K药援助政策再升级, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e39a18556630)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1618729, encodeId=cbfd1618e2959, content=<a href='/topic/show?id=89a810615bb' target=_blank style='color:#2F92EE;'>#K药#</a>, objectTitle=K药治疗中国食管癌生存率翻倍无论PD-L1表达 ——解读KEYNOTE-181中国亚组分析结果, objectType=article, longId=180885, objectId=c2e718088544, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c2e718088544, replyNumber=0, likeNumber=57, createdTime=2019-10-12, rootId=0, userName=12498e0fm84暂无昵称, userId=ae0619946966, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2e718088544, moduleTitle=K药治疗中国食管癌生存率翻倍无论PD-L1表达 ——解读KEYNOTE-181中国亚组分析结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c2e718088544)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1618728, encodeId=c2c11618e28f0, content=<a href='/topic/show?id=89a810615bb' target=_blank style='color:#2F92EE;'>#K药#</a>, objectTitle=肝癌治疗新进展：仑伐替尼+K药有望登顶肝细胞癌一线治疗, objectType=article, longId=177332, objectId=003a1e733254, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=003a1e733254, replyNumber=0, likeNumber=49, createdTime=2019-08-11, rootId=0, userName=12498e0fm84暂无昵称, userId=ae0619946966, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=003a1e733254, moduleTitle=肝癌治疗新进展：仑伐替尼+K药有望登顶肝细胞癌一线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=003a1e733254)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1618727, encodeId=1fb41618e2771, content=<a href='/topic/show?id=89a810615bb' target=_blank style='color:#2F92EE;'>#K药#</a>, objectTitle=“医二代”变多，日本网红眼药水被召回，默沙东K药单药疗法三期失败, objectType=article, longId=166910, objectId=06a21669103b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=06a21669103b, replyNumber=0, likeNumber=44, createdTime=2019-05-28, rootId=0, userName=12498e0fm84暂无昵称, userId=ae0619946966, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=06a21669103b, moduleTitle=“医二代”变多，日本网红眼药水被召回，默沙东K药单药疗法三期失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=06a21669103b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1618726, encodeId=9b691618e26b5, content=<a href='/topic/show?id=89a810615bb' target=_blank style='color:#2F92EE;'>#K药#</a>, objectTitle=O药一线治疗胶质母细胞瘤3期临床失败销量不及K药成定局？, objectType=article, longId=165870, objectId=a56a1658e0d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a56a1658e0d1, replyNumber=0, likeNumber=50, createdTime=2019-05-13, rootId=0, userName=12498e0fm84暂无昵称, userId=ae0619946966, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a56a1658e0d1, moduleTitle=O药一线治疗胶质母细胞瘤3期临床失败销量不及K药成定局？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a56a1658e0d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1618725, encodeId=8a4c1618e2518, content=<a href='/topic/show?id=89a810615bb' target=_blank style='color:#2F92EE;'>#K药#</a>, objectTitle=K药再拓疆土——细数晚期肾癌靶向治疗现状, objectType=article, longId=165608, objectId=279516560852, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=279516560852, replyNumber=0, likeNumber=49, createdTime=2019-05-09, rootId=0, userName=12498e0fm84暂无昵称, userId=ae0619946966, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=279516560852, moduleTitle=K药再拓疆土——细数晚期肾癌靶向治疗现状, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=279516560852)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1618724, encodeId=c96d1618e24e0, content=<a href='/topic/show?id=89a810615bb' target=_blank style='color:#2F92EE;'>#K药#</a>, objectTitle=K药重要临床试验总结及分析, objectType=article, longId=156010, objectId=e227156010a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e227156010a0, replyNumber=0, likeNumber=39, createdTime=2018-12-19, rootId=0, userName=12498e0fm84暂无昵称, userId=ae0619946966, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e227156010a0, moduleTitle=K药重要临床试验总结及分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e227156010a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1618723, encodeId=3a041618e2346, content=<a href='/topic/show?id=89a810615bb' target=_blank style='color:#2F92EE;'>#K药#</a>, objectTitle=和O药、K药争C位国产PD-1凭什么, objectType=article, longId=155255, objectId=242815525527, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=242815525527, replyNumber=0, likeNumber=54, createdTime=2018-12-08, rootId=0, userName=12498e0fm84暂无昵称, userId=ae0619946966, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=242815525527, moduleTitle=和O药、K药争C位国产PD-1凭什么, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=242815525527)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1618722, encodeId=84271618e228c, content=<a href='/topic/show?id=89a810615bb' target=_blank style='color:#2F92EE;'>#K药#</a>, objectTitle=O药 vs. K药论剑华山，11种癌症临床研究数据对比, objectType=article, longId=147145, objectId=279414e145c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=279414e145c4, replyNumber=0, likeNumber=45, createdTime=2018-08-22, rootId=0, userName=12498e0fm84暂无昵称, userId=ae0619946966, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=279414e145c4, moduleTitle=O药 vs. K药论剑华山，11种癌症临床研究数据对比, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=279414e145c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1618721, encodeId=dec51618e21ea, content=<a href='/topic/show?id=89a810615bb' target=_blank style='color:#2F92EE;'>#K药#</a>, objectTitle=K药今日正式登陆中国，新适应症加速获批, objectType=article, longId=147144, objectId=0a7d14e14421, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0a7d14e14421, replyNumber=0, likeNumber=47, createdTime=2018-08-22, rootId=0, userName=12498e0fm84暂无昵称, userId=ae0619946966, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0a7d14e14421, moduleTitle=K药今日正式登陆中国，新适应症加速获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0a7d14e14421)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

K药

2020-05-29

(审核中...)

前往app查看评论内容

全文收起与安慰剂相比，#派姆单抗##K药#显著延长了完全切除的IB-IIIA期#NSCLC#患者的无病生存期，无论#PD-L1#表达水平如何，而且无新的安全性问题。派姆单抗可作为完全切除后的IB-IIIA期NSCLC患者的新治疗选择。说明术后辅助也是有效的，那么如果术前做#新辅助治疗#，术后再做一段时间辅助，会不会更好？？

Lancet Oncol：派姆单抗辅助治疗可显著延长术后IB-IIIA期NSCLC患者的生存期

2022-09-20

12498e0fm84暂无昵称 (审核中...)

前往app查看评论内容

#K药#

NEJM重磅：K药一线治疗三阴乳腺癌OS结果终现！

2022-07-24

12498e0fm84暂无昵称 (审核中...)

前往app查看评论内容

#K药#

Lancet：全球半数病例在中国，K药为食管癌患者带来好消息！

2021-08-31

12498e0fm84暂无昵称 (审核中...)

前往app查看评论内容

#K药#

默沙东联合Surface开展联合疗法研究，或将改善K药耐药性

2021-04-05

12498e0fm84暂无昵称 (审核中...)

前往app查看评论内容

#K药#

K药在欧盟获批儿科适应症

2021-03-22

12498e0fm84暂无昵称 (审核中...)

前往app查看评论内容

#K药#

K药在欧盟获批儿科适应症

2021-03-20

12498e0fm84暂无昵称 (审核中...)

前往app查看评论内容

#K药#

K药，一年卖了930亿

2021-02-07

12498e0fm84暂无昵称 (审核中...)

前往app查看评论内容

#K药#

ASCO 2020：K药联合仑伐替尼的“可乐组合”在肾透明细胞癌再显威

2020-06-01

12498e0fm84暂无昵称 (审核中...)

前往app查看评论内容

#K药#

抢位K药？百济神州PD-1联合化疗一线治疗晚期鳞状非小细胞肺癌III期数据公布

2020-05-20

12498e0fm84暂无昵称 (审核中...)

前往app查看评论内容

#K药#

AACR 2020：STK11和KEAP1突变影响K药一线治疗PDL1阳性患者（Keynote 042研究）

2020-04-30

12498e0fm84暂无昵称 (审核中...)

前往app查看评论内容

#K药#

患者福音：门槛降低60%，K药援助政策再升级

2020-01-03

12498e0fm84暂无昵称 (审核中...)

前往app查看评论内容

#K药#

K药治疗中国食管癌生存率翻倍无论PD-L1表达 ——解读KEYNOTE-181中国亚组分析结果

2019-10-12

12498e0fm84暂无昵称 (审核中...)

前往app查看评论内容

#K药#

肝癌治疗新进展：仑伐替尼+K药有望登顶肝细胞癌一线治疗

2019-08-11

12498e0fm84暂无昵称 (审核中...)

前往app查看评论内容

#K药#

“医二代”变多，日本网红眼药水被召回，默沙东K药单药疗法三期失败

2019-05-28

12498e0fm84暂无昵称 (审核中...)

前往app查看评论内容

#K药#

O药一线治疗胶质母细胞瘤3期临床失败销量不及K药成定局？

2019-05-13

12498e0fm84暂无昵称 (审核中...)

前往app查看评论内容

#K药#

K药再拓疆土——细数晚期肾癌靶向治疗现状

2019-05-09

12498e0fm84暂无昵称 (审核中...)

前往app查看评论内容

#K药#

K药重要临床试验总结及分析

2018-12-19

12498e0fm84暂无昵称 (审核中...)

前往app查看评论内容

#K药#

和O药、K药争C位国产PD-1凭什么

2018-12-08

12498e0fm84暂无昵称 (审核中...)

前往app查看评论内容

#K药#

O药 vs. K药论剑华山，11种癌症临床研究数据对比

2018-08-22

12498e0fm84暂无昵称 (审核中...)

前往app查看评论内容

#K药#

K药今日正式登陆中国，新适应症加速获批

2018-08-22

科室
- - 订阅+
  - 更多科室
工具
服务